BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Phase 1/2 Recruiting
355 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
AHEAD-MERIT
Phase 2/3 Recruiting
350 enrolled
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
90 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 Recruiting
364 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
ASPEN-09-03
Phase 2 Recruiting
120 enrolled
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 Recruiting
700 enrolled
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
155 enrolled
ASCEND
Phase 1/2 Recruiting
290 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
595 enrolled
FIERCE-HN
Phase 3 Recruiting
410 enrolled
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Phase 2/3 Recruiting
982 enrolled
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
1,410 enrolled
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Phase 3 Recruiting
800 enrolled
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Phase 1/2 Recruiting
160 enrolled
BRIA-ABC
Phase 3 Recruiting
404 enrolled
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
Study of ABO2102 in KRAS-Mutated Solid Tumors
Phase 1 Recruiting
101 enrolled
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Phase 1/2 Recruiting
60 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 Recruiting
260 enrolled
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Phase 2/3 Recruiting
280 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Phase 1/2 Recruiting
114 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Phase 3 Recruiting
625 enrolled
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Phase 2 Recruiting
20 enrolled
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Phase 1/2 Recruiting
102 enrolled
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Phase 1/2 Recruiting
190 enrolled
INDIGO
Phase NA Recruiting
51 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Phase 1 Recruiting
70 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
STELLAR-311
Phase 2/3 Recruiting
440 enrolled
FORAGER-1
Phase 1 Recruiting
535 enrolled
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
120 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
STRIKE-001
Phase 1 Recruiting
144 enrolled
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 Recruiting
48 enrolled